PTCT insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 100% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 13 officers and directors who sold. 18 are left out

Left out: Michael Schmertzler, Matthew Klein, Neil Almstead, Mark Boulding, Eric Pauwels, Pierre Gravier, Christine Utter, Hege Sollie-Zetlmayer, David Southwell, Jerome Zeldis, Glenn Steele Jr., Mary Smith, Allan Jacobson, Alethia Young, Emma Reeve, Stephanie Okey, Lee Golden and Jessica Chutter (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Neil Almstead

Chief Technical Ops Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$22.4MDisclosed plan

Eric Pauwels

Chief Business Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$7.5MDisclosed plan

Michael Schmertzler

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$6.5MDisclosed plan

Mark Boulding

Exec. VP and CLO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.2MDisclosed plan

Matthew Klein

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.2MDisclosed plan

All 13 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Oct 7, 2026Michael Schmertzler sold 2.5K shares ($158K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Michael Schmertzler Director	2,500	$63.39	n/a	n/a	Oct 7, 2026	Oct 9, 2026

Oct 6, 2026Mark Boulding sold 435 shares ($28K) under a disclosed trading plan. 435 shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Mark Boulding Exec. VP and CLO	435	$64.16	n/a	n/a	Oct 6, 2026	Oct 7, 2026

Oct 5, 2026Mark Boulding sold 1.6K shares ($105K) under a disclosed trading plan. 1.6K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Mark Boulding Exec. VP and CLO	1,638	$64.03	n/a	n/a	Oct 5, 2026	Oct 7, 2026

Sep 30, 2026Glenn Steele Jr. sold 12K shares ($782K) under a disclosed trading plan. 12K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Glenn Steele Jr. Director	12,000	$65.16	n/a	n/a	Sep 30, 2026	Oct 2, 2026

Sep 17, 2026Michael Schmertzler sold 10K shares ($679K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Michael Schmertzler Director	10,000	$67.85	n/a	n/a	Sep 17, 2026	Sep 18, 2026

Show all 6 events

Sep 16, 2026Michael Schmertzler sold 10K shares ($671K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Michael Schmertzler Director	10,000	$67.12	n/a	n/a	Sep 16, 2026	Sep 18, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Ptc Therapeutics, Inc. CEO selling stock?

Yes. Matthew Klein sold 58K shares ($4.2M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Ptc Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 100% of sales by value ran under 10b5-1 trading plans disclosed in the filings. A trading plan schedules sales in advance.

Are any Ptc Therapeutics, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold13 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Neil Almstead Chief Technical Ops Officer	$22.4M 277K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Eric Pauwels Chief Business Officer	$7.5M 99K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Michael Schmertzler Director	$6.5M 93K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Mark Boulding Exec. VP and CLO	$4.2M 56K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Matthew Klein Chief Executive Officer, Director	$4.2M 58K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Emma Reeve Director	$2.5M 34K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Allan Jacobson Director	$2.1M 26K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Christine Utter SVP, Chief Accounting Officer	$1.9M 26K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Glenn Steele Jr. Director	$1.7M 24K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Stephanie Okey Director	$1.5M 22K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Mary Smith Director	$1.4M 16K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Lee Golden EVP & Chief Medical Officer	$1.1M 16K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Pierre Gravier Chief Financial Officer	$653K 8.6K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 18 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Michael Schmertzler

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Michael Schmertzler are complete.

Director

n/a

−93K

n/a

Vesting, gifts, unvested awards and holding lines for Michael Schmertzler

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Schmertzler are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,000	$25.69	Feb 14, 2034	$765K
17,600	$46.54	Jan 2, 2035	$306K
6,950	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Matthew Klein

Chief Executive Officer, Director

n/a

−58K

n/a

Vesting, gifts, unvested awards and holding lines for Matthew Klein

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Matthew Klein are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
175,000	$25.69	Feb 14, 2034	$6.7M
175,000	$46.54	Jan 2, 2035	$3.0M
157,500	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Neil Almstead

Chief Technical Ops Officer

n/a

−277K

n/a

Vesting, gifts, unvested awards and holding lines for Neil Almstead

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Neil Almstead are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
9,063	$39.42	Jan 4, 2033	$222K
23,751	$25.69	Feb 14, 2034	$909K
45,036	$46.54	Jan 2, 2035	$784K
43,750	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Mark Boulding

Exec. VP and CLO

n/a

−56K

n/a

Vesting, gifts, unvested awards and holding lines for Mark Boulding

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mark Boulding are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
6,798	$39.42	Jan 4, 2033	$167K
33,751	$25.69	Feb 14, 2034	$1.3M
3,070	$33.02	Jan 2, 2029	$95K
61,110	$33.02	Jan 2, 2029	$1.9M
28,125	$46.54	Jan 2, 2035	$490K
24,899	$25.69	Feb 14, 2034	$953K
16,876	$25.69	Feb 14, 2034	$646K
42,500	$76.74	Jan 1, 2036	$0
2,459	$39.42	Jan 4, 2033	$60K

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Eric Pauwels

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Eric Pauwels are complete.

Chief Business Officer

n/a

−99K

n/a

Vesting, gifts, unvested awards and holding lines for Eric Pauwels

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eric Pauwels are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
55,000	$25.69	Feb 14, 2034	$2.1M
55,000	$46.54	Jan 2, 2035	$958K
50,000	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Pierre Gravier

Chief Financial Officer

n/a

−8.6K

n/a

Vesting, gifts, unvested awards and holding lines for Pierre Gravier

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Pierre Gravier are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
47,500	$25.69	Feb 14, 2034	$1.8M
56,250	$46.54	Jan 2, 2035	$979K
50,000	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Christine Utter

SVP, Chief Accounting Officer

n/a

−26K

n/a

Vesting, gifts, unvested awards and holding lines for Christine Utter

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christine Utter are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,314	$25.69	Feb 14, 2034	$586K
35,000	$46.54	Jan 2, 2025	$609K
33,125	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Hege Sollie-Zetlmayer

Director

n/a

Vesting, gifts, unvested awards and holding lines for Hege Sollie-Zetlmayer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Hege Sollie-Zetlmayer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,000	$51.96	Oct 22, 2030	$168K
33,250	$66.49	Jan 5, 2031	$0
17,875	$38.10	Jan 6, 2032	$462K
11,250	$39.42	Jan 4, 2033	$276K
25,000	$25.69	Feb 14, 2034	$957K
25,000	$46.54	Jan 2, 2035	$435K
27,500	$76.74	Jan 1, 2036	$0
3,475	$75.39	Jul 27, 2036	$0
1,738	$75.39	Jul 27, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

David Southwell

Director

n/a

Vesting, gifts, unvested awards and holding lines for David Southwell

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Southwell are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$25.69	Feb 14, 2034	$383K
8,800	$46.54	Jan 2, 2035	$153K
3,475	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Jerome Zeldis

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jerome Zeldis

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jerome Zeldis are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$25.69	Feb 14, 2034	$383K
8,800	$46.54	Jan 2, 2035	$153K
3,475	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Glenn Steele Jr.

Director

n/a

−24K

n/a

Vesting, gifts, unvested awards and holding lines for Glenn Steele Jr.

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Glenn Steele Jr. are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$25.69	Feb 14, 2034	$383K
8,800	$46.54	Jan 2, 2035	$153K
3,475	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Mary Smith

Director

n/a

−16K

n/a

Vesting, gifts, unvested awards and holding lines for Mary Smith

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mary Smith are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$25.69	Feb 14, 2034	$383K
8,800	$46.54	Jan 2, 2035	$153K
3,475	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Allan Jacobson

Director

n/a

−26K

n/a

Vesting, gifts, unvested awards and holding lines for Allan Jacobson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Allan Jacobson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
12,000	$51.00	Jan 1, 2025	$155K
14,000	$33.02	Jan 21, 2029	$433K
10,000	$51.16	Jan 28, 2030	$128K
10,000	$66.49	Jan 5, 2031	$0
12,000	$38.10	Jan 6, 2032	$310K
10,000	$39.42	Jan 4, 2033	$245K
10,000	$25.69	Feb 14, 2034	$383K
8,800	$46.54	Jan 2, 2035	$153K
3,475	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Alethia Young

Director

n/a

Vesting, gifts, unvested awards and holding lines for Alethia Young

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alethia Young are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$25.69	Feb 14, 2034	$383K
8,800	$46.54	Jan 2, 2035	$153K
3,475	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Emma Reeve

Director

n/a

−34K

n/a

Vesting, gifts, unvested awards and holding lines for Emma Reeve

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Emma Reeve are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,475	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Stephanie Okey

Director

n/a

−22K

n/a

Vesting, gifts, unvested awards and holding lines for Stephanie Okey

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Stephanie Okey are complete; balances and unit counts will be added when the check is finished.

−867gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$25.69	Feb 14, 2034	$383K
8,800	$46.54	Jan 2, 2035	$153K
3,475	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Lee Golden

EVP & Chief Medical Officer

n/a

−16K

n/a

Vesting, gifts, unvested awards and holding lines for Lee Golden

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lee Golden are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
50,000	$25.69	Feb 14, 2034	$1.9M
50,000	$46.54	Jan 2, 2035	$871K
46,875	$76.74	Jan 1, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Jessica Chutter

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jessica Chutter

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jessica Chutter are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,475	$64.54	Mar 23, 2036	$0
2,896	$64.54	Mar 23, 2036	$0

Estimate: options held × ($63.95 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Holdings and share of stake for Ptc Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$57.7M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $57.7M across 755,008 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $57.7M · 100%

Taxes

$6.6M of sales (11.5%) cite tax obligations in their footnotes, $6.6M of them also under a plan. Example: Matthew Klein, Aug 4, 2026

Charitable gifts · 867 shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Neil Almstead Chief Technical Ops Officer	277K	$22.4M	100%	39%	Nov 24, 2025 to Jul 9, 2026
Eric Pauwels Chief Business Officer	99K	$7.5M	100%	13%	Dec 17, 2025 to Jun 10, 2026
Michael Schmertzler Director	93K	$6.5M	100%	11%	Aug 19, 2026 to Oct 7, 2026
Mark Boulding Exec. VP and CLO	56K	$4.2M	100%	7%	Nov 17, 2025 to Oct 6, 2026
Matthew Klein Chief Executive Officer, Director	58K	$4.2M	100%	7%	Dec 2, 2025 to Aug 4, 2026
Emma Reeve Director	34K	$2.5M	100%	4%	Oct 30, 2025 to Jan 5, 2026
Allan Jacobson Director	26K	$2.1M	100%	4%	Nov 24, 2025 to Nov 25, 2025
Christine Utter SVP, Chief Accounting Officer	26K	$1.9M	100%	3%	Jan 6, 2026 to Jun 17, 2026
Glenn Steele Jr. Director	24K	$1.7M	100%	3%	Jan 2, 2026 to Sep 30, 2026
Stephanie Okey Director	22K	$1.5M	100%	3%	Mar 5, 2026 to Mar 10, 2026
Mary Smith Director	16K	$1.4M	100%	2%	Jul 9, 2026 to Jul 9, 2026
Lee Golden EVP & Chief Medical Officer	16K	$1.1M	100%	2%	Jan 6, 2026 to Apr 2, 2026
Pierre Gravier Chief Financial Officer	8.6K	$653K	100%	1%	Jan 6, 2026 to Jul 14, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$1.1M	$1.1M	$0	$0
Nov 2025	$12.5M	$12.5M	$0	$0
Dec 2025	$5.8M	$5.8M	$0	$0
Jan 2026	$4.7M	$4.7M	$0	$0
Feb 2026	$2.1M	$2.1M	$0	$0
Mar 2026	$2.5M	$2.5M	$0	$0
Apr 2026	$4.0M	$4.0M	$0	$0
May 2026	$1.4M	$1.4M	$0	$0
Jun 2026	$8.8M	$8.8M	$0	$0
Jul 2026	$6.5M	$6.5M	$0	$0
Aug 2026	$4.5M	$4.5M	$0	$0
Sep 2026	$3.5M	$3.5M	$0	$0
Oct 2026	$291K	$291K	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 1.8x the 5-year average. 13 insiders sold; the average is 11 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	755K	13	$57.7M
Oct 13, 2025 1 year earlier	628K	12	$35.0M
Oct 13, 2024 2 years earlier	75K	10	$2.3M
Oct 14, 2023 3 years earlier	231K	12	$11.6M
Oct 14, 2022 4 years earlier	61K	9	$2.6M
Oct 14, 2021 5 years earlier	1.05M	12	$63.7M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty18 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Ptc Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology615 filings on record, 87 filed in the 12-month period, and how we read them

All 615 Forms 3, 4 and 5 on record for Ptc Therapeutics, Inc. (SEC CIK 1070081), filed from Jun 19, 2013 to Oct 9, 2026; 87 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (22)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
William Bell Jr.	Feb 16, 2024	10,333 shares, last reported balance as of Feb 15, 2024
Emily Hill	Mar 29, 2023	38,925 shares, last reported balance as of Mar 27, 2023
Stuart Peltz	Feb 2, 2023	221,865 shares, last reported balance as of Jan 31, 2023
Dawn Svoronos	Jun 10, 2022	29,017 shares, last reported balance as of Jun 9, 2022
Marcio Souza	Feb 12, 2020	56,841 shares, last reported balance as of Feb 10, 2020
Mark Rothera	May 25, 2017	42,955 shares, last reported balance as of May 24, 2017
Shane Kovacs	May 11, 2017	37,850 shares, last reported balance as of May 9, 2017
Complete Pharma Holdings II, LLC	May 2, 2017	No balance on record
Adam Koppel	Jan 5, 2017	1,083,333 shares, last reported balance as of Jun 25, 2013
Cameron McDonough	Jan 5, 2017	909 shares, last reported balance as of Jun 19, 2013
Ronald Renaud Jr.	Jan 5, 2017	No balance on record
Tuyen Ong	Jan 5, 2017	6,000 shares, last reported balance as of Jan 3, 2017
Adam Koppel	Jan 5, 2017	2,333,333 shares, last reported balance as of Jun 25, 2013
Robert Spiegel	Jan 6, 2016	3,239 shares, last reported balance as of Mar 13, 2015
Richard Aldrich	Jun 10, 2015	1,350,000 shares, last reported balance as of Jun 25, 2013
Michael Kranda	Mar 18, 2015	2,242 shares, last reported balance as of Mar 16, 2015
Claudia Hirawat	Jan 16, 2015	39,441 shares, last reported balance as of Jan 15, 2015
HBM Healthcare Investments (Cayman) Ltd.	Dec 19, 2013	2,441,504 shares, last reported balance as of Dec 17, 2013
Axel Bolte	Jun 27, 2013	20,000 shares, last reported balance as of Jun 25, 2013
CREDIT SUISSE AG/	Jun 27, 2013	2,256,882 shares, last reported balance as of Jun 25, 2013
Vulcan Ventures Inc.	Jun 25, 2013	1,701,731 shares, last reported balance as of Jun 25, 2013
Jay Barth	Jun 19, 2013	7,387 shares, last reported balance as of Jun 19, 2013

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Ptc Therapeutics, Inc. insiders sold $57.7M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Ptc Therapeutics, Inc. CEO selling stock?

Why are Ptc Therapeutics, Inc. insiders selling?

Are any Ptc Therapeutics, Inc. insiders buying?

The evidence

Taxes

Charitable gifts · 867 shares

Sales by month